Profile data is unavailable for this security.
About the company
Stoke Therapeutics, Inc. is a biotechnology company focused on addressing the underlying causes of severe genetic diseases by upregulating protein expression with ribonucleic acid-based medicines. Using its Targeted Augmentation of Nuclear Gene Output (TANGO) approach, the Company is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both the occurrence of seizures and non-seizure comorbidities. Its STK-002 is a ASO in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the OPA1 gene.
- Revenue in USD (TTM)8.78m
- Net income in USD-104.70m
- Incorporated2014
- Employees110.00
- LocationStoke Therapeutics Inc45 WIGGINS AVENUEBEDFORD 01730United StatesUSA
- Phone+1 (781) 430-8200
- Fax+1 (302) 531-3150
- Websitehttps://www.stoketherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compass Pathways PLC (ADR) | 0.00 | -118.46m | 610.16m | 186.00 | -- | 2.61 | -- | -- | -2.39 | -2.39 | 0.00 | 3.64 | 0.00 | -- | -- | 0.00 | -50.06 | -40.85 | -54.08 | -44.48 | -- | -- | -- | -- | -- | -- | 0.113 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
Cogent Biosciences Inc | 0.00 | -192.41m | 623.40m | 164.00 | -- | 2.84 | -- | -- | -2.40 | -2.40 | 0.00 | 2.99 | 0.00 | -- | -- | 0.00 | -62.65 | -49.53 | -70.07 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
Absci Corp | 5.72m | -110.57m | 624.83m | 155.00 | -- | 2.93 | -- | 109.27 | -1.20 | -1.20 | 0.0621 | 1.89 | 0.0212 | -- | 3.06 | 36,890.32 | -41.08 | -- | -46.22 | -- | -- | -- | -1,933.65 | -- | -- | -93.25 | 0.0467 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
Olema Pharmaceuticals Inc | 0.00 | -96.66m | 626.25m | 74.00 | -- | 2.43 | -- | -- | -2.16 | -2.16 | 0.00 | 4.62 | 0.00 | -- | -- | 0.00 | -39.24 | -30.06 | -42.54 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
OmniAB Inc | 34.16m | -50.62m | 631.31m | 106.00 | -- | 2.00 | -- | 18.48 | -0.4986 | -0.4986 | 0.3292 | 2.69 | 0.0858 | -- | 2.00 | 322,301.90 | -12.71 | -- | -13.55 | -- | -- | -- | -148.16 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Neurogene Inc | 0.00 | -36.32m | 633.14m | 91.00 | -- | 3.40 | -- | -- | -29.21 | -29.21 | 0.00 | 14.51 | 0.00 | -- | -- | 0.00 | -21.46 | -32.70 | -23.85 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
Mineralys Therapeutics Inc | 0.00 | -71.90m | 634.29m | 28.00 | -- | 2.18 | -- | -- | -1.79 | -1.79 | 0.00 | 5.86 | 0.00 | -- | -- | 0.00 | -39.28 | -- | -41.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Sinovac Biotech Ltd | 420.88m | -359.71m | 639.90m | 3.56k | -- | -- | -- | 1.52 | -3.63 | -3.63 | 3.94 | 87.08 | 0.0292 | 2.75 | 0.6035 | 118,289.80 | -5.09 | 55.60 | -7.77 | 93.17 | -46.96 | 91.39 | -174.00 | 67.88 | 9.74 | -- | 0.0174 | -- | -92.30 | 53.64 | -98.73 | 33.12 | 102.27 | -- |
Phathom Pharmaceuticals Inc | 682.00k | -201.59m | 646.17m | 452.00 | -- | -- | -- | 947.47 | -3.89 | -3.89 | 0.0133 | -1.26 | 0.0024 | -- | -- | 1,508.85 | -69.68 | -83.26 | -78.50 | -93.77 | 75.51 | -- | -29,558.94 | -135,982.00 | 10.22 | -4.91 | 1.20 | -- | -- | -- | -1.96 | -- | -- | -- |
Stoke Therapeutics Inc | 8.78m | -104.70m | 656.12m | 110.00 | -- | 4.08 | -- | 74.72 | -2.38 | -2.38 | 0.1996 | 3.47 | 0.0363 | -- | 26.94 | 79,827.27 | -43.23 | -31.62 | -49.60 | -33.92 | -- | -- | -1,192.34 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
ACELYRIN Inc | -100.00bn | -100.00bn | 657.04m | 51.00 | -- | 0.8962 | -- | -- | -- | -- | -- | 7.53 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.81 | -- | -- | -- |
Mind Medicine (MindMed) Inc | 0.00 | -95.73m | 667.55m | 57.00 | -- | 5.00 | -- | -- | -2.45 | -2.45 | 0.00 | 1.90 | 0.00 | -- | -- | 0.00 | -65.01 | -- | -78.34 | -- | -- | -- | -- | -- | -- | -- | 0.1531 | -- | -- | -- | -68.55 | -- | -- | -- |
Savara Inc | 0.00 | -54.70m | 670.02m | 37.00 | -- | 4.77 | -- | -- | -0.3424 | -0.3424 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -34.47 | -36.86 | -36.36 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.158 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Novavax Inc | 983.71m | -545.06m | 678.77m | 1.54k | -- | -- | -- | 0.69 | -5.53 | -5.53 | 9.42 | -5.14 | 0.485 | 8.76 | 5.18 | 637,527.60 | -26.88 | -46.06 | -- | -269.57 | 65.10 | -- | -55.41 | -75.94 | 0.6741 | -38.31 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Holder | Shares | % Held |
---|---|---|
RTW Investments LPas of 31 Dec 2023 | 4.13m | 9.25% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 3.36m | 7.52% |
Lynx1 Capital Management LPas of 31 Dec 2023 | 2.96m | 6.62% |
Redmile Group LLCas of 31 Dec 2023 | 2.63m | 5.88% |
Cowen & Co. LLCas of 04 Jan 2024 | 2.28m | 5.10% |
Baker Bros. Advisors LPas of 31 Dec 2023 | 2.03m | 4.55% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 1.82m | 4.07% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 1.63m | 3.64% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 1.33m | 2.97% |
Granahan Investment Management, LLCas of 31 Dec 2023 | 1.14m | 2.55% |